86,899 Shares in Alkermes plc (NASDAQ:ALKS) Purchased by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC purchased a new stake in shares of Alkermes plc (NASDAQ:ALKS) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 86,899 shares of the company’s stock, valued at approximately $2,499,000. Susquehanna Fundamental Investments LLC owned about 0.05% of Alkermes as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Avoro Capital Advisors LLC purchased a new position in Alkermes during the 4th quarter valued at approximately $70,462,000. Norges Bank purchased a new stake in Alkermes in the 4th quarter worth about $56,684,000. JPMorgan Chase & Co. grew its position in Alkermes by 147.4% in the 4th quarter. JPMorgan Chase & Co. now owns 889,472 shares of the company’s stock valued at $25,581,000 after acquiring an additional 529,962 shares during the last quarter. Raymond James Financial Inc. bought a new position in Alkermes in the 4th quarter worth about $12,293,000. Finally, Loomis Sayles & Co. L P increased its position in shares of Alkermes by 22.3% during the fourth quarter. Loomis Sayles & Co. L P now owns 2,302,905 shares of the company’s stock worth $66,232,000 after acquiring an additional 419,969 shares during the period. 95.21% of the stock is currently owned by institutional investors.

Insider Transactions at Alkermes

In other news, EVP Craig C. Hopkinson sold 144,419 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the completion of the sale, the executive vice president now directly owns 57,875 shares of the company’s stock, valued at $2,056,298.75. This trade represents a 71.39 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 4.40% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. HC Wainwright reiterated a “neutral” rating and set a $46.00 price objective on shares of Alkermes in a report on Thursday, February 13th. Royal Bank of Canada restated an “underperform” rating on shares of Alkermes in a research note on Monday. UBS Group reiterated a “sector perform” rating on shares of Alkermes in a research report on Monday. StockNews.com upgraded shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Finally, The Goldman Sachs Group raised their price target on shares of Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Alkermes currently has a consensus rating of “Moderate Buy” and an average target price of $38.08.

Alkermes Price Performance

Alkermes stock opened at $28.77 on Wednesday. Alkermes plc has a 12 month low of $22.90 and a 12 month high of $36.45. The company has a market cap of $4.74 billion, a price-to-earnings ratio of 13.26, a price-to-earnings-growth ratio of 2.20 and a beta of 0.39. The stock’s 50-day moving average is $31.62 and its 200-day moving average is $30.41.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. Research analysts anticipate that Alkermes plc will post 1.31 EPS for the current year.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.